Revised SPC: Vokanamet 50 mg/850 mg and 50 mg/1000 mg (canagliflozin /metformin) coated tablets

SPC now warns that post-marketing cases of complicated UTIs including pyelonephritis and urosepsis have been reported in patients treated with canagliflozin, frequently leading to treatment interruption. Temporary interruption should be considered if this occurs.

Source:

electronic Medicines compendium